IL6 and type 2 diabetes mellitus: In addition, Cana decreased serum leptin and interleukin-6 (IL-6), while it increased serum adiponectin and tumor necrosis factor alpha (TNF-alpha) in T2DM patients, which favorably impacted insulin sensitivity and CVD risk (Garvey et al., 2018).